340B Pay is the first-of-its-kind cloud-based solution that directly connects covered entities and manufacturers to request and receive 340B rebates, bringing a new level of ease and efficiency to a 30-year-old process.
A recent report from healthcare research firm 3 Axis Advisors provides the most complete picture to date of the operational impact that a 340B rebate model would have on covered entities. 3 Axis Advisors is a highly specialized consultancy with particular expertise in identifying U.S. drug supply chain inefficiencies and cost drivers.
A thorough analysis of the advantages that covered entities would experience is available in the whitepaper, "The Kalderos 340B rebate model in action."
Key findings in the 3 Axis report:
- Covered entities would receive faster payments from contract pharmacy dispenses.
- Covered entities would carry lower inventory costs.
- When rebates are based on WAC instead of contract pharmacy reimbursements tied to discounted AWP, covered entities gain access to incrementally higher revenue opportunities.